Taiwan Hemeilong

Hemay (Taiwan) Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for immune-mediated inflammatory diseases and oncology. As a subsidiary of Tianjin Hemay Pharmaceutical, the company manages clinical development and regulatory affairs for the group's pipeline in Taiwan and international markets. Its lead candidate, Hemay005, is an oral phosphodiesterase 4 (PDE4) inhibitor currently in Phase 3 clinical trials for the treatment of plaque psoriasis. The company's portfolio also includes targeted inhibitors for EGFR/HER2 and TNF-alpha, aiming to provide safer and more convenient oral alternatives to existing injectable therapies.